Table 1.
In vivo peripheral dose measurements with optically stimulated luminescence dosimeters for chin, pelvis, and breast areas
| Measurement point | Measured dose per fraction (cGy) | Total dose for 20 fractions (cGy) | TPS predicted total dose (cGy) | Difference between TPS and measurement (%) |
|---|---|---|---|---|
| Chin 1 | 2.04 | 40.8 | - | - |
| Chin 2 | 2.03 | 40.6 | - | - |
| Chin 3 | 2.05 | 41 | - | - |
| Pelvis 1 | 0.81 | 16.2 | - | - |
| Pelvis 2 | 0.85 | 17 | - | - |
| Pelvis 3 | 0.86 | 17.2 | - | - |
| Breast (average of 2 highest measurements) | 109.13 | 2182.6 | 2242.5 | −2.70% |
Abbreviation: TPS = treatment planning system.
Comparisons with the treatment planning system predictions are shown where available.